Halozyme Therapeutics Inc. (HALO)
NASDAQ
Closed
Aug 25, 2026
Day's Range
107.5552 wk Range
61.23Overview - HALO - Halozyme Therapeutics Inc.
Key Statistics
Valuation
Enterprise Value
14.22B
P/E (Trailing)
‪31.72‬
P/E (Forward)
‪10.40‬
PEG Ratio
‪0.71‬
Price / Sales (TTM)
‪7.37‬
Price / Book
‪85.91‬
EV / EBITDA
‪13.53‬
Profitability
Gross Margin
‪83.54%‬
Profit Margin
‪24.85%‬
Operating Margin
‪59.80%‬
Return on Assets
‪25.49%‬
Return on Equity
‪173.67%‬
Ownership
Shares Outstanding
118.61M
Float
112.16M
Short % of Shares Outstanding
‪16.19%‬
Held by Insiders
‪1.10%‬
Held by Institutions
‪112.34%‬
Price stats
Beta
‪0.84‬
50-Day Avg
‪83.04‬
200-Day Avg
‪72.27‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
9 analysts
Average price target
‪$ 99.56‬Shariah Compliance
Report Date: Feb 18, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - HALO - Halozyme Therapeutics Inc.
Peers - HALO - Halozyme Therapeutics Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- HALONASDAQHalozyme Therapeutics Inc.12.27BMarket Cap+33.24%52-week change31.72P/E (Trailing)‪24.85%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt63.39BMarket Cap+30.55%52-week change39.65P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals Inc31.58BMarket Cap-87.93%52-week change40.23P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE28.34BMarket Cap+7.12%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.52BMarket Cap+21.81%52-week change19.30P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.15.84BMarket Cap+39.72%52-week change-21.44P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBiomarin Pharmaceutical Inc.12.59BMarket Cap+11.71%52-week change180.27P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - HALO - Halozyme Therapeutics Inc.
About
Halozyme Therapeutics Inc. is a biopharmaceutical company that researches, develops, and commercializes proprietary enzymes and drug delivery technologies. Its core platform centers on the patented recombinant human hyaluronidase enzyme (rHuPH20), enabling subcutaneous administration of injectable biologics like…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
